1	Meta-Analysis of the Dynamics of the Emergence of Mutations and
2	Variants of SARS-CoV-2
3	
4	
5	Nicolas Castonguay <sup>1</sup> , Wandong Zhang <sup>2,3</sup> and Marc-Andre Langlois <sup>1,4*</sup>
6	
7	
8 9	<sup>1</sup> Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ontario, Canada K1H 8M5.
10 11	<sup>2</sup> Department of Cellular & Molecular Medicine, Faculty of Medicine, University of Ottawa, Ontario, Canada K1H 8M5.
12 13	<sup>3</sup> Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Canada K1A 0R6
14	<sup>4</sup> uOttawa Center for Infection, Immunity and Inflammation (CI3).
15	
16	
17	
18	Running title: Genome Evolution of SARS-CoV-2.
19	
20	*Correspondence should be addressed to: <u>langlois@uottawa.ca</u>
21	
22	

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

### 23 ABSTRACT

24 The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in late December 25 2019 in Wuhan, China, and is the causative agent for the worldwide COVID-19 pandemic. SARS-CoV-2 26 is a 29,811 nucleotides positive-sense single-stranded RNA virus belonging to the betacoronavirus genus. Due to inefficient proofreading ability of the viral RNA-dependent polymerase complex, coronaviruses 27 28 are known to acquire new mutations following replication, which constitutes one of the main factors 29 driving the evolution of its genome and the emergence of new genetic variants. In the last few months, the 30 identification of new B.1.1.7 (UK), B.1.351 (South Africa) and P.1 (Brazil) variants of concern (VOC) highlighted the importance of tracking the emergence of mutations in the SARS-CoV-2 genome and their 31 impact on transmissibility, infectivity, and neutralizing antibody escape capabilities. These VOC 32 demonstrate increased transmissibility and antibody escape, and reduce current vaccine efficacy. Here we 33 34 analyzed the appearance and prevalence trajectory of mutations that appeared in all SARS-CoV-2 genes 35 from December 2019 to January 2021. Our goals were to identify which modifications are the most 36 frequent, study the dynamics of their spread, their incorporation into the consensus sequence, and their 37 impact on virus biology. We also analyzed the structural properties of the spike glycoprotein of the 38 B.1.1.7, B.1.351 and P.1 variants. This study offers an integrative view of the emergence, disappearance, 39 and consensus sequence integration of successful mutations that constitute new SARS-CoV-2 variants 40 and their impact on neutralizing antibody therapeutics and vaccines.

41

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

#### 43 **IMPORTANCE**

the spike of VOCs.

44 SARS-CoV-2 is the etiological agent of COVID-19, which has caused > 2 million deaths worldwide as of 45 January, 2021. Mutations occur in the genome of SARS-CoV-2 during viral replication and affect viral 46 infectivity, transmissibility and virulence. In early March 2020, the D614G mutation in the spike protein emerged, which increased the viral transmissibility and is now found in >90% of all SARS-CoV-2 47 genomic sequences in GISAID database. Between October and December 2020, B.1.1.7 (UK), B.1.351 48 (South Africa) and P.1 (Brazil) variants of concern (VOCs) emerged, which have increased neutralizing 49 50 antibody escape capabilities because of mutations in the receptor binding domain of the spike protein. 51 Characterizing mutations in these variants is crucial because of their effect on adaptive immune response, 52 neutralizing antibody therapy, and their impact on vaccine efficacy. Here we tracked and analyzed 53 mutations in SARS-CoV-2 genes over a twelve-month period and investigated functional alterations in

55

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

#### 56 INTRODUCTION

57 In late December 2019, a new betacoronavirus known as Severe Acute Respiratory Syndrome 58 Coronavirus 2 (SARS-COV-2) emerged in Wuhan, the province of Hubei, China (1), SARS-CoV-2 is the 59 etiological agent for the worldwide COVID-19 pandemic resulting in more than 90 million infected and 2 million death worldwide as of Dec. 2020 (2,3). SARS-CoV-2 is an enveloped, positive-sense single-60 stranded RNA (+ssRNA) virus with a genome length of 26,000 to 32,000 bps (4). The mutation rates of 61 62 RNA viruses are generally higher than that of DNA viruses because of the low fidelity of their viral RNA 63 polymerases (5,6). Mutations occur when viral replication enzymes introduce errors in the viral genome 64 resulting in the creation of premature termination codons, deletions and insertions of nucleotides that can 65 change open reading frames, and changes in the nucleotide sequence that can result in amino acid 66 substitutions in the viral proteins. These mutations combined with the selective pressure of the human 67 immune system leads to the selection and evolution of viral genomes (6,7). However, coronaviruses are 68 one of the few members of the RNA virus family that possess limited but measurable proofreading ability via the 3' to 5' exoribonuclease activity of the non-structural viral protein 14 (nsp14) (8,9). Coronaviruses 69 70 are therefore expected to evolve through genetic drift much slower than other RNA viruses that do not 71 have this ability, such as influenza and HIV (8,10). Additionally, SARS-CoV-2 and other coronaviruses 72 have low known occurrences of recombination between family members (i.e., genetic shift), and therefore 73 are mostly susceptible to genetic drift (11).

74 SARS-CoV-2 has reached pandemic status due to its presence on every continent and has since 75 maintained a high level of transmissibility across hosts of varied ethnical and genetic backgrounds (2, 12). 76 Moreover, SARS-CoV-2 infections have been reported to naturally infect minks, ferrets, cats, and dogs, 77 which allows the virus to replicate in completely new hosts and mutate to produce new variants and 78 possibly new strains (13,14). In March 2020, the now dominant D614G mutation first emerged in the 79 spike protein (S) of SARS-CoV-2. The S protein is present as a trimer at the surface of the viral envelope 80 and is responsible for attachment of the virus to the human angiotensin converting enzyme 2 (hACE2), 81 the entry receptor for SARS-CoV-2 (15). Published evidence has now shown that D614G increases viral 82 fitness, transmissibility and viral load but does not directly affect COVID-19 pathogenicity (16,17,18,19). Additionally, emerging evidence indicates that D614G may have epistatic interactions and exacerbate the 83 84 impact of several other independent mutations (19). Mutations in the S protein, and particularly in 85 receptor binding domain (RBD), are of very high concern given that they can direct influence viral infectivity, transmissibility and resistance to neutralizing antibodies and T cell responses. 86

New mutations are frequently and regularly detected in the genome of SARS-CoV-2 through whole
genome sequencing, however very few of these mutations make it into the viral consensus sequence. The

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

consensus sequence or reference strain is generally regarded as the dominant transmitted strain at a given time. This sequence is determined by aligning large numbers of recently sequenced genomes and establishing a consensus of the highest frequency nucleotide for each position in the viral genome. A genetic variant is a version of the reference strain that has acquire one or several mutations and acts as the founder for further genetic diversification. Mutations arise regularly in the reference strain, but few are longitudinally conserved. Genetic variants are therefore successful offshoots of the reference strain.

95 Some variants rise rapidly in frequency and then collapse and disappear, others will rise and overtake the 96 frequency of the reference strain and become the new reference, while others acquire additional mutations 97 and continue their upward prevalence trajectory and evolution. There are three main genetic variants that 98 have emerged in the past few months with a sustained upward frequency trajectory. The UK and South 99 African variants have been reported in September and October 2020, respectively (20,21,22), while the 100 P.1/501Y.N3 (P.1) variant is a branch off of the B.1.1.28 lineage, was first detected in travelers from 101 Brazil that landed in Japan in January 2021 (23). These variants are associated with increased resistance 102 to neutralizing antibodies (Nabs) (24). The UK variant known as B.1.1.7/501Y.V1 (B1.1.7) is present worldwide with local transmission in Europe, China, Oceania, North and South America (20,21). The 103 104 South African variant also known as B.1.352/501Y.V2 (B.1.351) has reported local transmission in the 105 South African region, Europe, and North America (21,22). The P.1. variant has since been identified in 106 42% of specimens in the Amazonian city of Manaus and was detected for the first time in the U.S. at the 107 end of January 2021 (landed in Japan in January 2021) (23). All these variants possess the N501Y 108 mutation, which is a mutation in the RBD that is critical for the spike to interact with hACE2 (25). This 109 mutation is reported to cause increased resistance to Nabs, increased infectivity, and virulence in animal models (26). In addition to the N501Y mutation, both the South African and Brazil variants possesses 110 111 RBD mutations K417N and E484K, which are also associated with increased Nabs escape capabilities 112 (24).

Here we present a retrospective metadata analysis study of mutations reaching higher than 1% global frequency occurring throughout the SARS-CoV-2 genome over the past year and we specifically investigate their frequency trajectory over time and their fixation into the reference sequencing using the Global Initiative on Sharing Avian Influenza Data (GISAID) (27). Additionally, we analyzed mutations in the S protein of the B.1.1.7, B.1.351 and P.1 variants and illustrated their impact on molecular interactions between the S protein and hACE2 and their potential impact on Nabs.

119

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

#### 121 MATERIALS AND METHODS

#### 122 Data collection and mutational analysis

Genomes uploaded to the GISAID EpiCoV<sup>TM</sup> server database were analyzed from December 1<sup>st</sup>, 2019, to 123 December 31<sup>st</sup>, 2020, with collection of viral sequences from December 1<sup>st</sup>, 2019 to January 6, 2021. The 124 125 mutations were selected by being in more than 500 reported genomes in August 2020, and another selection 126 was made in January 2021 to capture mutations with more than 4000 reported genomes. Thus, allowing us to 127 study mutations reaching at least 1% in global frequency. We filtered through 309,962 genomes for the analysis of selected mutations. The variants hCoV-19/Wuhan, hCoV-19/D614G, B.1.1.7, B.1.351, and P.1 128 were analyzed from December 1<sup>st</sup>, 2019 to February 17<sup>th</sup>, 2021. The collection dates were the same dates as the 129 analysis. For the analysis of the mutations in B.1.1.7, B.1.351, and P.1 variants, we used the GISAID 130 EpiCoV<sup>TM</sup> server database and analyzed the mutations in the variants from December 1<sup>st</sup>, 2019, to February 131 17<sup>th</sup>, 2021. The same timeline was used for the collection dates of the viral sequences. We filtered through 132 133 429,514 genomes for the analysis of the variants. Only complete SARS-CoV-2 genomes (28 to 30 Kbps) 134 isolated from human hosts were analyzed. MUSCLE alignment tool on UGene, and SnapGene was used to 135 determine the nucleotide mutations and codon changes of the non-synonymous and synonymous mutations by 136 sequence alignments with NCBI SARS-CoV-2 reference genome (NC\_045512). We acknowledge all 137 genomes uploaded to the GISAID database, and aligned genomes used for Tables 1, 2, 3 and 4 are presented 138 in supplementary material 1. Graphs of mutations and variants were performed on RStudio with timelines, and

139 genomes illustrations were produced in Biorender.

#### 140 Structural modeling

- 141 Mutations in the spike protein in complex with hACE2 were analyzed using a mutagenesis tool on PyMOL
- 142 (PDB: 7A94). Visualization of mutations in the B.1.1.7, B.1.351 and P.1 variants was produced using the
- spike protein closed conformation (PDB: 6ZGE), interaction with hACE2 (PDB: 7A94), interaction with C102
- 144 Nab (PDB: 7K8M), and interaction with C121 Nab (PDB: 7K8X). Figures and rendering were prepared with
- 145 PyMOL.
- 146

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

#### 147 **RESULTS**

148 Identification of emerging mutations in various SARS-CoV-2 genes. Emerging mutations in the 149 SARS-CoV-2 genome were investigated to determine the fluctuations of these mutations during a period 150 of twelve months. We compiled mutations reported in 500> genomes in August, and 4000> genomes in 151 from the GISAID database, and followed their appearance in reported SARS-CoV-2 early January 152 genomes until December 31th, 2020. Genes NSP8, NSP10, NS6, NS7a, and E are not illustrated in Figure 1 given that did not display mutation frequencies sufficiently high to meet our inclusion 153 154 conditions during the periods of data collection of our study. This is also indicative that these appear to be 155 the most conserved sequences of the SARS-CoV-2 genome. Our analysis focused on the emergence, 156 fixation, and fading of the mutations analyzed that met our inclusion criteria. Our analysis highlights the 157 fixation of the D614G mutation in the S protein and the P323L in the RdRp (Fig.1). Both are the only 158 mutations to have been successful to reach reference strain status until now. They appeared to have 159 emerged simultaneously in January, 2020 and became present in >90% of all sequenced genomes by 160 June, 2020. However, some other mutations emerged rapidly and then stabilized or faded out. For 161 example, Q57H (NS3), R203K (N), G204R (N) are mutations that emerged rapidly and appeared to have 162 stabilized at a frequency of 15% to 40%. Others like I120F (NSP2), L37F (NSP6), S477N (S), and L84S 163 (NS8) illustrate mutations that emerged rapidly and then faded-out. We also demonstrate that most genes 164 in SARS-CoV-2 have mutations with frequencies lower than 10% (Fig.1). Also, these mutations are 165 summarized into Table 1, which illustrates nucleotide substitution producing the amino acid change, the frequency at the end of 2020 and their respective effects. (Table 1). These results indicate that only 166 D614G (S) and P323L (NSP12) were fixed in the viral consensus sequence, many of the mutations either 167 168 faded out or emerged and then stabilized at a frequency lower than 50%.

169 Geographic localization and timeline of the viral genes with mutations higher than 50% frequency. 170 To further study the mutations that have frequencies higher than 50%, we took the graphs of NSP12, S, and N genes from Figure 1 and added worldwide geographic locations of the mutations provided from 171 172 GISAID. These maps are useful to track down if a mutation is a localized and regional event or found 173 worldwide. In the S protein, D614G is found worldwide with higher reported cases in the US, UK, and 174 Australia, probably due to more large-scale testing, while A222V is mostly reported in the UK, but has 175 not been reported in South America, Central and East African regions (Fig. 2A). Like D614G, P323L in 176 the RdRp is also found worldwide, with higher reported cases in the US, UK, and Australia (Fig. 2B). 177 The N gene doesn't have successful mutations that have attained reference strain status, but R203K, 178 G204R and A220V all had a frequency of 50% or higher during the past twelve months. Even if R203K 179 and G204R frequencies have decreasing since July of 2020 and stabilized in November of 2020, both

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

180 mutations are currently found worldwide. A220V emerged in August of 2020 and reached a frequency 181 higher than 50% in October of 2020. Mutations G204R, R203K and A220V are reported at high 182 frequency in the UK, but have not been detected in South America, Central, East, and South African 183 regions (**Fig. 2C**). The analyses of these data illustrate the localization of the most prevalent mutations to 184 date, which appear to be mostly present in Western and developed countries. This, however, is 185 undoubtable attributable to overall more testing.

186 Localization and molecular interactions of recurrent S protein mutations. Here we illustrated the 187 molecular interactions and spatial localization of the mutations in the S protein. PyMOL was used to 188 model the structures of S protein and analyze the possible effects of specific mutations at given positions 189 in the protein. Figure 3A presents an overview of the localization of the S protein mutations and their 190 interactions with their environment. The A222V mutation has no reported effects on protein stability, 191 neutralizing antibody escape, and affinity for hACE2 (Table 1). The substitution from A to V results in a 192 low steric clash between neighboring residues (Fig. 3B). The S477N substitution in the RBD enables 193 increased stability during hACE2-RBD interactions (Table 1, Fig. 3C). In the N-terminal domain (NTD), mutagenesis of L18F leads to a steric clash between neighboring residues (Fig. 3D). However, this does 194 195 not appear to impact the stability of the protein given that no such effects have been reported for L18F so 196 far (Table 1). In the closed conformation, D614 makes an ionic bond with K854 in the S2 subunit of 197 another S protein monomer (Fig. 3F) (28). In the open conformation, D614 (or G614) doesn't make 198 interactions or display steric clashes with neighboring residues (Fig. 3E).

199 The emergence of the B.1.1.7 variant in the UK. A new variant was discovered in late 2020 in the UK 200 that displayed increased affinity to hACE2 and Nabs escape capabilities (24,29,30). Here we attempted to 201 further investigate the B.1.1.7 variant by looking at S protein mutations of this variant in complex with 202 Nabs and hACE2. We mapped the localization of the mutations with available Cryo-EM structures of the 203 S protein and assessed the frequency of the variant by interrogating the GISAID database. There are nine 204 mutations in the S protein out of the total 24 mutations in the B.1.1.7 SARS-CoV-2 genome (Fig. 5A & 205 **5E**). Deletions and mutations in the S protein of the B.1.1.7 variant, apart from D614G, emerged in 206 October of 2020 and reached a frequency of 68% to 72% mid February (Fig. 4, Fig. 5C, Table 2). N501Y is found in the RBD and can interact with a lysine residue in hACE2 (Fig. 5B & 5D, Fig. 8C). 207 208 The N501Y mutation is associated with an increased affinity to hACE2, along with an increase in 209 infectivity and virulence (Table 2). Figure 5E illustrates the whole genome of SARS-CoV-2 with all 210 nucleotide substitutions of the B.1.1.7 variant. The C913T, C5986T, C14676T, C15279T, C16176T in 211 ORF1ab, and T26801C in M protein are synonymous mutations. Also, the C27972T mutation has a frequency of 71% and produces a premature stop codon in NS8 that inactivates the protein (O27stop) 212

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

without obvious consequences (Fig. 5E, Table 2) (31). These results allow us to better understand the frequencies, localization, and interactions of mutations in the S protein of the B.1.1.7 variant. Importantly, for viruses, not only synonymous mutations are of important. Non-synonymous mutations can exercise very important roles at various stages of the viral infection cycle, such as replication and creating functional RNA loops that serve as docking points for ribonucleoproteins and primers.

218 The emergence of the B.1.351 variant in South Africa. During the emergence of the B.1.1.7 variant in 219 the UK, another variant was emerging in South Africa, known as B.1.351 (21.22). Similar to Figure 5. 220 we illustrate the mutations in S protein and their respective frequencies. The GISAID database was used 221 to track down mutations and Cryo-EM structures of the S protein to model the effects of point mutations. Most of the mutations in the S protein of the B.1.351 variant are localized in the S1 subunit, with only 222 223 A701V in the S2 subunit. Additionally, three mutations reside in the RBD, among which two of them are 224 not found in the B.1.1.7 variant (K417N, E484K) (Fig. 6A & 6B). This variant contains the D614G and 225 N501Y, which are also seen in the B.1.1.7 variant (Fig. 5A). Furthermore, many of the mutations found in the B.1.351 variant have global frequencies lower than 2%. The exception is D614G, L18F and N501Y 226 227 (Fig. 6C, Table 3). In comparison to B.1.1.7 and P.1 variants, B.1.351 variant has not reached a 228 frequency higher than 1% as of mid February 2021 (Fig. 4). By using the mutagenesis tool of PyMOL, 229 we modeled the S protein in complex with hACE2, and with C103 and C121 Nabs, which are human 230 recombinant class I & II neutralizing antibodies, respectively(32). Our in silico mutagenesis predicts that 231 mutations in the RBD induce a loss of interactions with C102 Nab and C121 Nab. At the position 417 in 232 the S protein, a loss of interaction is predicted between the RBD and C102 Nab when the K417 is mutated 233 to Asn producing Nabs escape capability. (Fig. 6D & 8A). Another loss of interaction is predicted with the E484K mutation and the C121 Nab, which could lead to Nabs escape capability (Fig. 6E & 8B). As 234 235 previously mentioned, N501Y is also found in the B.1.351 strain and our modeling predicts that it will 236 have similar effects as those observed with the B.1.1.7 variant (Fig. 6F). Figure 6G illustrates the 237 nucleotide substitutions of the B.1.351 variant.

The emergence of the P.1 variant in Brazil. Similar to the B.1351 variant, the P.1 variant harbours the 238 239 N501Y and E484K mutations, but position 417 of the S protein displays a threonine instead of a lysine residue (19.23). Similar to the UK and South African variants, we demonstrate mutations in the S protein 240 producing the P.1 variant and their frequencies from December 2019 to 17<sup>th</sup> of February 2021 (Fig. 7). 241 The P.1 variant harbours substitutions L18F, T20N, P26S, D138Y, and R190S in the NTD of the S 242 243 protein. H655Y and T1027I are in the subdomain 2 (SD2) and S2 subunit, respectively (Fig. 7A & 7B, 244 Table 4). Overall, P.1-specific mutations have worldwide frequencies less than 2% (Fig. 7C, Table 4). D614G, L18F and N501Y are not specific to P1. Similar to B.1.351, P.1 variant has low global frequency 245

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

with less than 1% of global variant frequency as of mid February 2021 (Fig. 4). We then modeled
mutations to investigate interaction alterations with known recombinant neutralizing antibodies (32). The
K417T mutation reduces interactions with neighboring residues in the C102 Nab and therefore we
predict, as with K417N in B.1.1.7, an increased ability to escape neutralization (Fig. 7D). Also, the P.1
variant has E484K, and N501Y mutations in the RBD. We predict they will have the same effect reported
for the B.1.1.7, and B.1.351 variants (Fig. 7E & 7F). In Figure 7G, we illustrate the synonymous, nonsynonymous, and deletions in SARS-CoV-2 P.1 genome (Table 4).

253

#### 254 **DISCUSSION**

255 Research on the effect of mutations in SARS-CoV-2 has been carried out since the appearance of the 256 virus, and the emergence of new genetic variants that are more transmissible and resistant to antibody 257 neutralization have highlighted the importance of studying these mutations. The number of sequenced 258 viral genomes uploaded to the GISAID database grew fast from 131,417 at the end of September to 259 451,913 by January 30<sup>th</sup>, 2021 (27). GISAID is a formidable tool for tracking the emergence of 260 mutations, identifying the region where it emerged, and track its spread around the globe. Given the risk mutations and new variants pose for neutralizing antibody therapy and vaccines for SARS-CoV-2, it is 261 262 crucial to continuously monitor the susceptibility of these variants to neutralization by humoral and 263 cellular immune responses either induced through natural exposure to the reference strain or induced by 264 vaccination (24). Recent reports on the vaccine efficacy of the Moderna, Pfizer-BioNTech, and Oxford-AstraZeneca vaccines against the B.1.1.7 and B.1.351 variant is variable. All of these vaccines remain 265 efficacious against the B.1.1.7 variant (30,33,34). However, the Oxford-AstraZeneca vaccine has 266 267 displayed compromised efficacy against the B.1.351 variant with 21.4% (35). Preliminary data with the 268 Pfizer-BioNTech and Moderna mRNA vaccines also show reduction of efficacy against B.1.351 (34,36). 269 Furthermore, antibodies induced by the Pfizer-BioNTech vaccine appear to display a 15.1-fold decrease 270 in neutralization efficacy against the P.1 variant (37) (Table 5). Nevertheless, humoral responses are only 271 one component of the adaptive immune response. T and B cell responses have not been probed in detail 272 against these variants at this time and may still provide robust protection.

Furthermore, there is likely epistatic mutations in the S protein. Epistasis is the combinatory effect of two or more mutations in a genome (41). Epistasis has previously been studied in the surface protein hemagglutinin (HA) of the influenza viruses, and have illustrated positive epistasis in 11 regions of the HA receptor-binding domain (42). In relation to the S protein of SARS-CoV-2, it could, for instance, allow the S protein to adopt a specific conformation when all the mutations are present, thereby producing

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

278 a unique folding of the protein. A recent study demonstrated the impact of antigenicity and infectivity of 279 the D614G SARS-CoV-2 variants with a combination of different mutations occurring in the S protein 280 (19). The study shows that D614G alone increases infectivity, but in combination with different other mutations in the S protein, these can either increase or decrease viral infectivity. Similar findings have 281 282 been reported regarding sensitivity to Nabs. D614G alone has undetectable effects on Nabs escape. However, the combination of D614G with other mutations in S can enable Nabs escape. This data 283 284 suggests that the continuous emergence of epistatic mutations in SARS-CoV-2 will likely be involved in further altering properties of the virus, including transmissibility, pathogenicity, stability and Nab 285 286 resistance.

Our analyses have highlighted that several of the successful mutations analyzed had frequency trajectories 287 288 that eventually plunged or stabilized at low frequencies. Only the D614G in the S protein and the P323L 289 in the RdRp maintained their presence in the consensus sequence (Fig. 1 & 2). Analyses of the GISAID 290 database also reveal which countries upload the most sequences to the database and are therefore carrying 291 out the most testing and sequencing. The global frequency of mutations and variants in the database is therefore biased to represent the genetic landscape of the countries doing the most testing. Emergence of 292 293 new variants may therefore go undetected until they leave their point of origin and enter countries with 294 high testing and sequencing rates. This delayed notification constitutes a major obstacle in preventing the 295 spread of nefarious variants that are potentially resistant to current vaccines and neutralizing antibody 296 therapy.

297 In conclusion, our metadata analysis of emerging mutations has highlighted the natural upward and 298 downward fluctuation in mutation prevalence. We also illustrate how mutations sometimes need to co-299 emerge in order to create a favorable outcome for virus propagation. Tracking mutations and the 300 evolution of the SARS-CoV-2 genome is critical for the development and deployment of effective 301 treatments and vaccines. Thus, it is the responsibility of all countries and governing jurisdictions to 302 increase testing and sequencing and upload SARS-CoV-2 genomes to databases in real-time. On then will 303 we have the most accurate information to inform policy and decisions makers about interventions 304 required to blunt the global transmission of the virus and ensure that our tools remain effective against the 305 all circulating variants.

Castonguay et al., 2020 Genome Evolution of SARS-CoV-2

#### 307 ACKNOWLEDGEMENTS

- 308 The authors wish to thank Sean Li for helpful comments on our manuscript. M.-A.L. holds a Canada
- 309 Research Chair in Molecular Virology and Intrinsic Immunity. This study was supported by a COVID-19
- 310 Rapid Response grant to M-A Langlois by the Canadian Institute of Health Research (CIHR) and by a
- 311 grant supplement by the Canadian Immunity Task Force (CITF).

312

## 313 CONFLICTS OF INTERESTS

314 The authors declare no competing interests.

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

#### 315 **REFERENCES**

- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P,
   Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. 2020. A Novel Coronavirus from
   Patients with Pneumonia in China, 2019. *N Engl J Med* 382:727–733.
- Dong E, Du H, Gardner L. 2020. An interactive web-based dashboard to track COVID-19 in
   real time. *The Lancet Infectious Diseases* 20:533–534.
- Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y,
   Yuan M-L, Zhang Y-L, Dai F-H, Liu Y, Wang Q-M, Zheng J-J, Xu L, Holmes EC, Zhang
   Y-Z. 2020. A new coronavirus associated with human respiratory disease in China. *Nature* 579:265–269.
- 4. Kim D, Lee J-Y, Yang J-S, Kim JW, Kim VN, Chang H. 2020. The Architecture of SARSCoV-2 Transcriptome. *Cell 181*:914-921.e10.
- 327 5. Duffy S. 2018. Why are RNA virus mutation rates so damn high? *PLOS Biology*328 16:e3000003.
- 329 6. Mandary MB, Masomian M, Poh CL. 2019. Impact of RNA Virus Evolution on
  330 Quasispecies Formation and Virulence. *Int J Mol Sci* 20:4657.
- 331 7. Duffy S, Shackelton LA, Holmes EC. 2008. Rates of evolutionary change in viruses: patterns
  and determinants. *Nature Reviews Genetics* 9:267–276.
- 8. Eckerle LD, Becker MM, Halpin RA, Li K, Venter E, Lu X, Scherbakova S, Graham RL,
   Baric RS, Stockwell TB, Spiro DJ, Denison MR. 2010. Infidelity of SARS-CoV Nsp14 Exonuclease Mutant Virus Replication Is Revealed by Complete Genome Sequencing. *PLOS Pathogens* 6:e1000896.
- Minskaia E, Hertzig T, Gorbalenya AE, Campanacci V, Cambillau C, Canard B, Ziebuhr J.
   2006. Discovery of an RNA virus 3'→5' exoribonuclease that is critically involved in
   coronavirus RNA synthesis. *Proc Natl Acad Sci U S A* 103:5108.
- 10. Ma Y, Wu L, Shaw N, Gao Y, Wang J, Sun Y, Lou Z, Yan L, Zhang R, Rao Z. 2015.

Castonguay et al., 2020 Genome Evolution of SARS-CoV-2

- Structural basis and functional analysis of the SARS coronavirus nsp14–nsp10 complex.
   *Proc Natl Acad Sci USA* 112:9436.
- 11. Rausch JW, Capoferri AA, Katusiime MG, Patro SC, Kearney MF. 2020. Low genetic
  diversity may be an Achilles heel of SARS-CoV-2. *Proc Natl Acad Sci USA* 117:24614.
- 12. Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, Monego SD,
  Pantano E, Manganaro N, Manenti A, Manna R, Casa E, Hyseni I, Benincasa L, Montomoli
  E, Amaro RE, McLellan JS, Rappuoli R. 2020. SARS-CoV-2 escape *in vitro* from a highly
  neutralizing COVID-19 convalescent plasma. *bioRxiv* 2020.12.28.424451.
- 13. Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z, Zhao Y,
- Liu P, Liang L, Cui P, Wang J, Zhang X, Guan Y, Tan W, Wu G, Chen H, Bu Z. 2020.
- Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. *Science* 368:1016.
- 14. Li X, Giorgi EE, Marichannegowda MH, Foley B, Xiao C, Kong X-P, Chen Y, Gnanakaran
  S, Korber B, Gao F. 2020. Emergence of SARS-CoV-2 through recombination and strong
  purifying selection. *Sci Adv* 6:eabb9153.
- 356 15. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. 2020. Structure,
  357 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 181:281-292.e6.
- 16. Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou
  J, Fontes-Garfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B,
  Freiberg AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi P-Y. 2020. Spike mutation
  D614G alters SARS-CoV-2 fitness. *Nature* https://doi.org/10.1038/s41586-020-2895-3.
- 362 17. Zhang L, Jackson CB, Mou H, Ojha A, Peng H, Quinlan BD, Rangarajan ES, Pan A,
  363 Vanderheiden A, Suthar MS, Li W, Izard T, Rader C, Farzan M, Choe H. 2020. SARS-CoV364 2 spike-protein D614G mutation increases virion spike density and infectivity. *Nature*365 *Communications* 11:6013.
- 18. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N,
  Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM,

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

- Freeman TM, de Silva TI, Angyal A, Brown RL, Carrilero L, Green LR, Groves DC,
  Johnson KJ, Keeley AJ, Lindsey BB, Parsons PJ, Raza M, Rowland-Jones S, Smith N,
  Tucker RM, Wang D, Wyles MD, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan
  SP, LaBranche CC, Saphire EO, Montefiori DC. 2020. Tracking Changes in SARS-CoV-2
  Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell* 182:812827.e19.
- 19. Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, Qin H, Wang M,
  Lu Q, Li X, Sun Q, Liu J, Zhang L, Li X, Huang W, Wang Y. 2020. The Impact of
  Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. *Cell*, 2020/07/17 ed.
  182:1284-1294.e9.
- 20. Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, Connor T, Peacock T,
  Robertson D, Volz E, on behalf of CoG-UK. 2020. Preliminary genomic characterisation of
  an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations.
  <u>https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-</u>
  lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563
- 21. O'Toole, A, Hill V, et al. (2021) Tracking the international spread of SARS-CoV-2 lineage
   B.1.1.7 and B.1.351/501Y-V2. <u>https://virological.org/t/tracking-the-international-spread-of-</u>
   <u>sars-cov-2-lineages-b-1-1-7-and-b-1-351-501y-v2/592</u>
- 386 22. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, 387 Pillay S, San EJ, Msomi N, Mlisana K, von Gottberg A, Walaza S, Allam M, Ismail A, Mohale T, Glass AJ, Engelbrecht S, Van Zyl G, Preiser W, Petruccione F, Sigal A, Hardie D, 388 Marais G, Hsiao M, Korsman S, Davies M-A, Tyers L, Mudau I, York D, Maslo C, 389 390 Goedhals D, Abrahams S, Laguda-Akingba O, Alisoltani-Dehkordi A, Godzik A, Wibmer CK, Sewell BT, Lourenço J, Alcantara LCJ, Pond SLK, Weaver S, Martin D, Lessells RJ, 391 Bhiman JN, Williamson C, de Oliveira T. 2020. Emergence and rapid spread of a new severe 392 393 acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv 2020.12.21.20248640. 394

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

- 23. Faria, Nuno R.; et al. (12 January 2021). Genomic characterisation of an emergent SARS-
- CoV-2 lineage in Manaus: preliminary findings. *Virological*. Retrieved 23 January 2021.
- 399 https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-
- 400 <u>manaus-preliminary-findings/586</u>
- 401 24. Wang P, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS,
  402 Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Nair
  403 MS, Huang Y, Ho DD. 2021. Increased Resistance of SARS-CoV-2 Variants B.1.351 and
  404 B.1.1.7 to Antibody Neutralization. *bioRxiv* 2021.01.25.428137.
- 405 25. Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, Lu X, Zhang Y, Ma L, Gu W, Qu A, Xu J, Shi Z,
  406 Ling Z, Sun B. 2020. Key residues of the receptor binding motif in the spike protein of
  407 SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. *Cellular & Molecular*408 *Immunology* 17:621–630.
- 409 26. Gu H, Chen Q, Yang G, He L, Fan H, Deng Y-Q, Wang Y, Teng Y, Zhao Z, Cui Y, Li Y, Li
- 410 X-F, Li J, Zhang N-N, Yang X, Chen S, Guo Y, Zhao G, Wang X, Luo D-Y, Wang H, Yang
- 411 X, Li Y, Han G, He Y, Zhou X, Geng S, Sheng X, Jiang S, Sun S, Qin C-F, Zhou Y. 2020.
- 412 Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. *Science* 369:1603.
- 413 27. Shu Y, McCauley J. 2017. GISAID: Global initiative on sharing all influenza data from
  414 vision to reality. *Euro Surveill* 22:30494.
- 28. Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ.
  2020. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane
  fusion. *Nature* 588:327–330.
- 29. Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, Navarro MJ,
  Bowen JE, Tortorici MA, Walls AC, King NP, Veesler D, Bloom JD. 2020. Deep Mutational
  Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and
  ACE2 Binding. *Cell* 182:1295-1310.e20.
- 422 30. Muik A, Wallisch A-K, Sänger B, Swanson KA, Mühl J, Chen W, Cai H, Maurus D, Sarkar

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

- R, Türeci Ö, Dormitzer PR, Şahin U. 2021. Neutralization of SARS-CoV-2 lineage B.1.1.7
  pseudovirus by BNT162b2 vaccine–elicited human sera. *Science* eabg6105.
- 425 31. Pereira F. 2020. Evolutionary dynamics of the SARS-CoV-2 ORF8 accessory gene. *Infect*426 *Genet Evol*, 2020/09/02 ed. 85:104525–104525.
- 32. Barnes CO, Jette CA, Abernathy ME, Dam K-MA, Esswein SR, Gristick HB, Malyutin AG,
  Sharaf NG, Huey-Tubman KE, Lee YE, Robbiani DF, Nussenzweig MC, West AP,
  Bjorkman PJ. 2020. SARS-CoV-2 neutralizing antibody structures inform therapeutic
  strategies. *Nature* 588:682–687.
- 33. Emary KR, Golubchik T, Aley PK, Ariani CV, Angus BJ, Bibi S, Blane B, Bonsall D,
  Cicconi P, Charlton S. 2021. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against
  SARS-CoV-2 VOC 202012/01 (B. 1.1. 7).
- 34. Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, Colpitts T, Bennett
  H, Boyoglu-Barnum S, Shi W, Moliva JI, Sullivan NJ, Graham BS, Carfi A, Corbett KS,
  Seder RA, Edwards DK. 2021. Serum Neutralizing Activity Elicited by mRNA-1273
  Vaccine *Preliminary Report. N Engl J Med* <u>https://doi.org/10.1056/NEJMc2102179</u>
- 438 35. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Kwatra G, Ahmed K, Aley P, Bhikha S, Bhiman JN, 439 440 Bhorat AE, Plessis J du, Esmail A, Groenewald M, Horne E, Hwa S-H, Jose A, Lambe T, 441 Laubscher M, Malahleha M, Masenya M, Masilela M, McKenzie S, Molapo K, Moultrie A, 442 Oelofse S, Patel F, Pillay S, Rhead S, Rodel H, Rossouw L, Taoushanis C, Tegally H, 443 Thombrayil A, Eck S van, Wibmer CK, Durham NM, Kelly EJ, Villafana TL, Gilbert S, 444 Pollard AJ, de Oliveira T, Moore PL, Sigal A, Izu A. 2021. Safety and efficacy of the 445 ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South 446 Africa. *medRxiv* 2021.02.10.21251247.
- 447 36. Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, Cai H, Sarkar R, Chen W,
  448 Cutler M, Cooper D, Weaver SC, Muik A, Sahin U, Jansen KU, Xie X, Dormitzer PR, Shi P449 Y. 2021. Neutralizing Activity of BNT162b2-Elicited Serum *Preliminary Report. N Engl*450 *J Med* https://doi.org/10.1056/NEJMc2102017.

Castonguay et al., 2020

457

Genome Evolution of SARS-CoV-2

- 37. Garcia-Beltran WF, Lam EC, Denis KSt, Nitido AD, Garcia ZH, Hauser BM, Feldman J,
  Pavlovic MN, Gregory DJ, Poznansky MC, Sigal A, Schmidt AG, Iafrate AJ, Naranbhai V,
  Balazs AB. 2021. Circulating SARS-CoV-2 variants escape neutralization by vaccineinduced humoral immunity. *medRxiv* 2021.02.14.21251704.
- 455 38. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc
- 456 G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina

WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan

- 458 DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. 2020. Safety and Efficacy
- 459 of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 383:2603–2615.
- 39. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA,
  Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C,
  Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J,
  Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng
  W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T. 2020. Efficacy and Safety of the mRNA1273 SARS-CoV-2 Vaccine. *N Engl J Med* 384:403–416.
- 466 40. Voysey M, Clemens SAC, Madhi SA, et al. 2021. Safety and efficacy of the ChAdOx1
  467 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
  468 controlled trials in Brazil, South Africa, and the UK. *The Lancet* 397:99–111.
- 469 41. Phillips PC. 2008. Epistasis the essential role of gene interactions in the structure and
  470 evolution of genetic systems. *Nature Reviews Genetics* 9:855–867.
- 471 42. Wu NC, Xie J, Zheng T, Nycholat CM, Grande G, Paulson JC, Lerner RA, Wilson IA. 2017.
  472 Diversity of Functionally Permissive Sequences in the Receptor-Binding Site of Influenza
  473 Hemagglutinin. *Cell Host & Microbe* 21:742-753.e8.
- 474 43. COVID-19 GENOMIC UK CONSORTIUM. 2021. COG-UK report on SARS-CoV-2 Spike
  475 mutations of interest in the UK. <u>https://www.cogconsortium.uk/wp-</u>
  476 <u>content/uploads/2021/01/Report-2\_COG-UK\_SARS-CoV-2-Mutations.pdf</u>
- 477 44. Zahradník J, Marciano S, Shemesh M, Zoler E, Chiaravalli J, Meyer B, Rudich Y, Dym O,

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

- Elad N, Schreiber G. 2021. SARS-CoV-2 RBD *in vitro* evolution follows contagious
  mutation spread, yet generates an able infection inhibitor. *bioRxiv* 2021.01.06.425392.
- 480 45. Kannan SR, Spratt AN, Quinn TP, Heng X, Lorson CL, Sönnerborg A, Byrareddy SN, Singh
  481 K. 2020. Infectivity of SARS-CoV-2: there Is Something More than D614G? J
  482 *Neuroimmune Pharmacol*, 2020/09/15 ed. 15:574–577.
- 483 46. Ugurel OM, Mutlu O, Sariyer E, Kocer S, Ugurel E, Inci TG, Ata O, Turgut-Balik D. 2020.
  484 Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2
  485 helicase (Nsp13). *Int J Biol Macromol*, 2020/09/24 ed. 163:1687–1696.
- 486 47. Wu S, Tian C, Liu P, Guo D, Zheng W, Huang X, Zhang Y, Liu L. 2020. Effects of SARS-
- 487 CoV-2 mutations on protein structures and intraviral protein–protein interactions. *Journal of* 488 *Medical Virology* n/a.

489

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

## 491 TABLES

Gene	Genome Nucleotide Mutation	Codon	AA Mutation	Frequency (%)*	Effect
S	Mutation	GAT to GGT	D614G	00.70	Moderate increase in
2	A23403G	GAT to GGT	D614G	99.70	Moderate increase in Transmissibility <sup>43</sup>
	C22227T	GCT to GTT	A222V	42.79	No mutational effect <sup>43</sup>
	C21615T	CTT to TTT	L18F	19.86	N/A
	G22992A	AGC to AAC	S477N	5.36	Spike-hACE2 complex stability and Nab interference <sup>42</sup>
	C22879A	AAC to AAA	N439K	4.09	Antibody Escape ability <sup>19</sup>
	C21575T	CTT to TTT	L5F	1.44	N/A
	C21855T	TCT to TTT	S98F	2.74	N/A
	G22346T	GCT to TCT	A262S	1.64	N/A
NSP1	C335T	CGC to TGC	R24C	0.70	N/A
NSP2	A1163T	ATT to TTT	I120F	0.74	N/A
	G1210T	ATG to ATT	M135I	0.124	N/A
	C1059T	ACC to ATC	T85I	5.55	N/A
	T1947C	GTT to GCT	V381A	0.55	N/A
	C2453T	CTC to TTC	L550F	2.73	N/A
NSP3	C7926T	GCA to GTA	A1736V	1.23	N/A
1101 0	G2891A	GCA to ACA	A58T	0.03	N/A
	T7767C	ATC to ACC	I1683T	4.05	N/A
	C5622T	CCT to CTT	P968L	0.63	N/A
	G8371T	CAG to CAT	Q1884H	0.05	N/A N/A
	C4002T	ACT to ATT	T428I	0.38	N/A N/A
	C5388A	GCT to GAT	A890D	21.37	N/A N/A
	G8083A	ATG to $ATA$	M1788I	1.23	N/A N/A
	C3602T	CAC to TAC	H295Y	2.51	N/A N/A
NSP4	C9246T	GCT to GTT	A231V	0.12	N/A N/A
NSF4	G9526T	ATG to $ATT$	M324I	5.18	N/A N/A
		AAG to AGG	K90R	1.60	N/A N/A
NSP5	A10323G G10097A	GGT to AGT	G15S	0.36	N/A N/A
NSFJ	G10097A G10265A	GGT to AGT	G71S	0.69	N/A N/A
NSP6	C10319T	CTT to <b>T</b> TT G <b>C</b> T to G <b>T</b> T	L89F A46V	3.21 0.08	N/A N/A
NSFO	C11109T				N/A N/A
	C11396T	CTT to TTT	L142F	2.64 2.73	N/A N/A
	G11083T	TTG to TTT	L37F		
	C11195T	CTT to TTT	L75F	0.05	N/A
	G11230T	ATG to ATT $CCT \leftarrow ACT$	M86I	0.52	N/A
	G11801A	GGT to AGT	G277S	0.01	N/A
	G11132T 11288-11296 del	<b>GCT</b> to <b>TCT</b>	A54S	1.83	N/A
MCD7		N/A	∆S106	22.50	N/A
NSP7	G12067T	ATG to ATT	M75I	0.171	N/A
NGDO	C11916T	TCA to TTA	S25L	0.06	N/A
NSP9	G12988T	ATG to ATT	M101I	3.20	N/A
NSP12	C14408T	CCT to CTT	P323L	99.53	Improve processivity, by interaction with NSP8 <sup>45</sup>
	G15766T	GTG to TTG	V776L	5.27	N/A
	G13993T	GCT to TCT	A185S	5.22	N/A
	G15598A	GTC to ATC	V720I	3.21	N/A
	G14202T	GAG to GAT	E254D	0.68	N/A
10012	C13730T	GCT to GTT	A97V	0.04	N/A
NSP13	C16289T	GCT to GTT	A18V	0.05	N/A
	G17019T	GAG to GAT	E261D	5.20	N/A
	C17104T	CAT to TAT	H290Y	4.20	N/A
	C17747T	CCT to CTT	P504L	0.10	Increase hydrophobicity of 2 <i>A</i> domain <sup>46</sup>

**Table 1:** Non-synonymous mutations in SARS-CoV-2 genes with a worldwide frequency >0.01%.

Genome Evolution of SARS-CoV-2

A17615G         AAG to AGG         K460R         10.20         N/A           A16889G         AAA to AGA         K218R         5.18         N/A           G18028T         GCA to TCA         A598S         3.21         N/A           NSP14         C18998T         GCA to GTA         A320V         0.02         N/A           G19542T         ATG to ATT         M5011         0.71         N/A           A18424G         AAT to GAT         M129D         3.00         N/A           A18424G         AAT to GAT         T331         1.78         N/A           NSP15         C19718T         ACa to ATA         T331         1.78         N/A           A21390G         TTA to TTG         R216C         2.77         N/A           A228580T         GAT to TAT         D103Y         0.13         N/A           G28580T         GAT to TAT         D103Y         0.13         N/A           G28882C         GGA to CGA         G204R         29.55         Destabilizing N protein <sup>47</sup> C28893T         CCA to CTA         P194L         0.65         N/A           G28882A         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup>		C17639T	TCA to TTA	S468L	0.02	N/A
A16889G         AA to AGA         K218R         5.18         N/A           NSP14         G18028T         GCA to TCA         A598S         3.21         N/A           NSP14         C18998T         GCA to GTA         A320V         0.02         N/A           G19542T         ATG to ATT         M5011         0.71         N/A           A18424G         AAT to GAT         T331         1.78         N/A           NSP16         A21137G         AAG to AGG         K160R         0.39         N/A           NSP16         A21137G         AAG to AGG         K160R         0.39         N/A           A21390G         TTA to TTG         R216C         2.77         N/A           Q28580T         GAT to TAT         D103Y         0.13         N/A           G28883C         GGA to CGA         G204R         29.55         Destabilizing N protein <sup>47</sup> C28869T         CCA to CTA         P199L         5.55         N/A           G28852A         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C28854T         TCA to TTA         D31L         2.2.01         N/A           G28975C         ATG to ATC         M32         2.01						
G18028T         GCA to TCA         A598S         3.21         N/A           NSP14         C18998T         GCA to GTA         A320V         0.02         N/A           C18568T         CTC to TTC         L177F         0.16         N/A           A18424G         AAT to GAT         N129D         3.00         N/A           A18424G         AAT to GAT         T131         1.78         N/A           NSP16         A21137G         AAG to AGG         K160R         0.39         N/A           A21390G         TTA to TTG         R216C         2.77         N/A           G28830T         GAT to TAT         D103Y         0.13         N/A           G28832C         GGA to CA         G204R         29.55         Destabilizing N protein <sup>47</sup> C28831T         CCC to CTC         P13L         0.27         N/A           G28882AA         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C28852TA         GAT to TA         D31         22.01         N/A           G28975C         ATG to ATC         M234I         5.58         N/A           G28975C         ATG to ATT         D31L         22.01         N/A <t< th=""><td></td><td></td><td></td><td></td><td></td><td></td></t<>						
NSP14         C18998T         GCA to GTA         A320V         0.02         N/A           C18568T         CTC to TTC         L177F         0.16         N/A           G19542T         ATG to ATT         M5011         0.71         N/A           A18424G         AAT to GAT         N129D         3.00         N/A           NSP15         C19718T         ACA to ATA         T331         1.78         N/A           NSP16         A21137G         AAG to AGG         K160R         0.39         N/A           A13130G         TTA to TTG         R216C         2.77         N/A           A21390G         TTA to TTG         R216C         2.77         N/A           G28832T         GCT to GTT         A220V         46.41         N/A           G28883C         GGA to CGA         G204R         29.55         Destabilizing N protein <sup>47</sup> C28311T         CCC to CTC         P13L         0.27         N/A           G28882A         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C28854T         TCA to TTA         S194L         4.65         Destabilizing N protein <sup>47</sup> C28877T         ATC to ATC         M234I         5.58						
Classes         CTC to TTC         L177F         0.16         N/A           GI9542T         ATG to ATT         M5011         0.71         N/A           A18424G         AAT to GAT         N129D         3.00         N/A           NSP15         C19718T         ACA to ATA         T331         1.78         N/A           NSP16         A21137G         AAG to AGG         K160R         0.39         N/A           A21390G         TTA to TTG         R216C         2.77         N/A           C28932T         GCT to GTT         A2202V         46.41         N/A           G28580T         GAT to TAT         D103Y         0.13         N/A           G2883C         GGA to CGA         G204R         29.55         Destabilizing N protein <sup>47</sup> C28311T         CCC to CTC         P13L         0.27         N/A           G28882AA         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C2887T         TCA to TTA         S194L         4.65         Destabilizing N protein <sup>47</sup> C2887T         GAT to TAT         D3L         22.01         N/A           G29399A         GCT to ATT         D37TY         1.29         N/A     <	NSP14					
G19542T         ATG to ATT         M501I         0.71         N/A           A18424G         AAT to GAT         N129D         3.00         N/A           NSP15         C19718T         ACA to ATA         T331         1.78         N/A           NSP16         A21137G         AAG to AGG         K160R         0.39         N/A           A21390G         TTA to TTG         R216C         2.77         N/A           Q28932T         GCT to GTT         A220V         46.41         N/A           G28880T         GAT to TAT         D103Y         0.13         N/A           G28880T         GCA to CCA         G204R         29.55         Destabilizing N protein <sup>47</sup> C28869T         CCA to CTA         P199L         5.55         N/A           G28882AA         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C28854T         TCA to TTA         S194L         4.65         Destabilizing N protein <sup>47</sup> C28854T         TCA to TCA         D3L         22.01         N/A           G28975C         ATG to ATC         M234I         5.58         N/A           G28975C         ATG to ATA         D377Y         1.29         N/A	1151 14					
A18424G         AAT to GAT         N129D         3.00         N/A           NSP15         C19718T         ACA to ATA         T331         1.78         N/A           NSP16         A21137G         AAG to AGG         K160R         0.39         N/A           A211390G         TTA to TTG         R216C         2.77         N/A           N         C28932T         GCT to GTT         A220V         46.41         N/A           G28880T         GAT to TAT         D103Y         0.13         N/A           G28883C         GGA to CA         G204R         29.55         Destabilizing N protein <sup>47</sup> C28369T         CCA to CTA         P199L         5.55         N/A           G28882AA         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C28854T         TCA to TTA         S194L         4.65         Destabilizing N protein <sup>47</sup> C28852TA         GAT to CTA         D3L         22.01         N/A           G28975C         ATG to ATC         M234I         5.58         N/A           G29399A         GCT to ACT         A376T         5.14         N/A           C29366T         CCA to TAA         P365S         5.64						
NSP15         Cl9718T         ACA to ATA         T331         1.78         N/A           NSP16         A21137G         AAG to AGG         K160R         0.39         N/A           A21390G         TTA to TTG         R216C         2.77         N/A           N         C28932T         GCT to GTT         A220V         46.41         N/A           G28580T         GAT to TAT         D103Y         0.13         N/A           G28883C         GGA to CGA         G204R         29.55         Destabilizing N protein <sup>47</sup> C28311T         CCC to CTA         P191L         5.55         N/A           C28869T         CCA to CTA         P199L         5.55         N/A           G28882AA         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C28869T         TCA to TTA         S194L         4.65         Destabilizing N protein <sup>47</sup> C28854T         TCA to TA         D3L         22.01         N/A           GAT28282CTA         GAT to CTA         D3L         22.01         N/A           G28975C         ATG to ATC         M234I         5.58         N/A           C28472T         CCT to TCT         P67S         3.09						
NSP16         A21137G         AAG to AGG         K160R         0.39         N/A           A21390G         TTA to TTG         R216C         2.77         N/A           N         C28932T         GCT to GTT         A220V         46.41         N/A           G28580T         GAT to TAT         D103Y         0.13         N/A           G28580T         GAT to TAT         D103Y         0.13         N/A           G28883C         GGA to CGA         G204R         29.55         Destabilizing N protein <sup>47</sup> C28869T         CCA to CTC         P13L         0.27         N/A           GC28882AA         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C2854T         TCA to TTA         S194L         4.65         Destabilizing N protein <sup>47</sup> C2897T         TCT to TTT         S235F         22.01         N/A           G28975C         ATG to ATC         M2341         5.58         N/A           C28472T         CCT to TCT         P67S         3.09         N/A           G29399A         GCT to ATT         D37TY         1.29         N/A           C2887T         ACT to ATT         D37TY         1.29         N/A <td>NSP15</td> <td></td> <td></td> <td></td> <td></td> <td></td>	NSP15					
A21390G         TTA to TTG         R216C         2.77         N/A           N         C28932T         GCT to GTT         A220V         46.41         N/A           G28580T         GAT to TAT         D103Y         0.13         N/A           G2883C         GGA to CGA         G204R         29.55         Destabilizing N protein <sup>47</sup> C28311T         CCC to CTC         P13L         0.27         N/A           C28854T         CCA to CTA         P199L         5.55         N/A           GC28882AA         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C2854T         TCA to TTA         S194L         4.65         Destabilizing N protein <sup>47</sup> C28854T         TCT to TTT         S235F         22.01         N/A           GAT28282CTA         GAT to CTA         D3L         22.01         N/A           G28975C         ATG to ATC         M2341         5.58         N/A           C28472T         CCT to TCT         P67S         3.09         N/A           G29399A         GCT to ACT         A376T         5.14         N/A           C28472T         GAT to TAT         D377Y         1.29         N/A						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	10110					
G28580T         GAT to TAT         D103Y         0.13         N/A           G28883C         GGA to CGA         G204R         29.55         Destabilizing N protein <sup>47</sup> C28311T         CCC to CTC         P13L         0.27         N/A           C28869T         CCA to CTA         P199L         5.55         N/A           GC2882AA         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C2885T         TCA to TTA         S194L         4.65         Destabilizing N protein <sup>47</sup> C2897TT         TCT to TTT         S235F         22.01         N/A           GAT28282CTA         GAT to CTA         D3L         22.01         N/A           G28975C         ATG to ATC         M234I         5.58         N/A           G29399A         GCT to ACT         A376T         5.14         N/A           G29402T         GAT to TAT         D377Y         1.29         N/A           C28887T         ACT to ATT         T051         1.47         N/A           C29366T         CCA to TCA         P365S         5.64         N/A           C29366T         GCA to GTA         A398V         0.78         N/A           C28887T	N					
G28883C         GGA to CGA         G204R         29.55         Destabilizing N protein <sup>47</sup> C28311T         CCC to CTC         P13L         0.27         N/A           C28869T         CCA to CTA         P199L         5.55         N/A           GC28882AA         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C28854T         TCA to TTA         S194L         4.65         Destabilizing N protein <sup>47</sup> C28854T         TCA to TTT         S235F         22.01         N/A           GAT28282CTA         GAT to CTA         D3L         22.01         N/A           G28975C         ATG to ATC         M2341         5.58         N/A           C28472T         CCT to TCT         P67S         3.09         N/A           G29399A         GCT to ACT         A376T         5.14         N/A           C29366T         CCA to TCA         P365S         5.64         N/A           C2887T         ACT to ATT         T205I         1.47         N/A           C29402T         GAT to GT         D3G         0.42         N/A           C29466T         GCA to GTA         A398V         0.78         N/A           C27046T	14					
C28311T         CCC to CTC         P13L         0.27         N/A           C28869T         CCA to CTA         P199L         5.55         N/A           GC28882AA         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C28854T         TCA to TTA         S194L         4.65         Destabilizing N protein <sup>47</sup> C28854T         TCA to TTT         S235F         22.01         N/A           GAT28282CTA         GAT to CTA         D3L         22.01         N/A           G28975C         ATG to ATC         M234I         5.58         N/A           G28975C         ATG to ATC         M234I         5.58         N/A           G28975C         ATG to ATC         M234I         5.58         N/A           G28472T         CCT to TCT         P67S         3.09         N/A           G29399A         GCT to ATT         A376T         5.14         N/A           G29402T         GAT to TAT         T205I         1.47         N/A           C28887T         ACT to ATT         T205I         1.47         N/A           C29466T         GCA to GTA         A398V         0.78         N/A           C27046T         ACG to ATG <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
C28869T         CCA to CTA         P199L         5.55         N/A           GC28882AA         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C28854T         TCA to TTA         S194L         4.65         Destabilizing N protein <sup>47</sup> C28977T         TCT to TTT         S235F         22.01         N/A           GAT28282CTA         GAT to CTA         D3L         22.01         N/A           G28975C         ATG to ATC         M234I         5.58         N/A           C28472T         CCT to TCT         P67S         3.09         N/A           G29399A         GCT to ACT         A376T         5.14         N/A           C29366T         CCA to TCA         P365S         5.64         N/A           C29366T         GCA to ATT         D377Y         1.29         N/A           C29466T         GCA to GTA         A398V         0.78         N/A           C29466T         GCA to GTA         A398V         0.78         N/A           M         A26530G         GAT to GGT         D30         0.42         N/A           C29466T         GCA to ATG         T175M         0.02         N/A           G25503T						
GC28882AA         AGC to AAA         R203K         29.74         Destabilizing N protein <sup>47</sup> C28854T         TCA to TTA         \$194L         4.65         Destabilizing N protein <sup>47</sup> C28977T         TCT to TTT         \$235F         22.01         N/A           GAT28282CTA         GAT to CTA         D3L         22.01         N/A           G28975C         ATG to ATC         M234I         5.58         N/A           C28472T         CCT to TCT         P67S         3.09         N/A           G29399A         GCT to ACT         A376T         5.14         N/A           C29366T         CCA to TCA         P365S         5.64         N/A           C2887T         ACT to ATT         D3G         N/A           C28887T         ACT to ATT         T205I         1.47         N/A           C29466T         GCA to GTA         A398V         0.78         N/A           C29466T         ACG to ATG         T175M         0.02         N/A           M         A26530G         GAT to GTT         G172V         2.98         N/A           MS3         G25907T         GGT to GTT         T223I         1.87         N/A           G25617T         <						
C28854T         TCA to TTA         S194L         4.65         Destabilizing N protein <sup>47</sup> C28977T         TCT to TTT         S235F         22.01         N/A           GAT28282CTA         GAT to CTA         D3L         22.01         N/A           G28975C         ATG to ATC         M234I         5.58         N/A           C28472T         CCT to TCT         P67S         3.09         N/A           G29399A         GCT to ACT         A376T         5.14         N/A           C29366T         CCA to TCA         P365S         5.64         N/A           G29402T         GAT to ATT         D3G         0.42         N/A           C28887T         ACT to ATT         T205I         1.47         N/A           C29466T         GCA to GTA         A398V         0.78         N/A           C27046T         ACG to ATG         T175M         0.02         N/A           NS3         G25907T         GGT to GTT         G172V         2.98         N/A           G2563T         CAG to CAT         Q57H         13.00         N/A           G25429T         GTA to TTA         V202L         2.64         N/A           G25429T         GTA to TTA						
C28977T         TCT to TTT         S235F         22.01         N/A           GAT28282CTA         GAT to CTA         D3L         22.01         N/A           G28975C         ATG to ATC         M2341         5.58         N/A           C28472T         CCT to TCT         P67S         3.09         N/A           G29399A         GCT to ACT         A376T         5.14         N/A           G2936GT         CCA to TCA         P365S         5.64         N/A           G29402T         GAT to TAT         D37Y         1.29         N/A           C28887T         ACT to ATT         T205I         1.47         N/A           C29466T         GCA to GTA         A398V         0.78         N/A           C29466T         GCA to GT         D3G         0.42         N/A           C27046T         ACG to ATG         T175M         0.02         N/A           M         A26530G         GAT to GT         G3G         0.42         N/A           G2561T         ACG to AAT         K75N         0.39         N/A           G2561TT         AAG to AAT         K75N         0.39         N/A           G25600T         ACT to ATT         T223I         1.8						
GAT28282CTA       GAT to CTA       D3L       22.01       N/A         G28975C       ATG to ATC       M234I       5.58       N/A         C28472T       CCT to TCT       P67S       3.09       N/A         G29399A       GCT to ACT       A376T       5.14       N/A         C29366T       CCA to TCA       P365S       5.64       N/A         G29402T       GAT to TAT       D377Y       1.29       N/A         C28887T       ACT to ATT       T205I       1.47       N/A         C29466T       GCA to GTA       A398V       0.78       N/A         C29466T       GCA to GT       D3G       0.42       N/A         C27046T       ACG to ATG       T175M       0.02       N/A         C27046T       ACG to AT       T175N       0.39       N/A         MS3       G25907T       GGT to GT       G172V       2.98       N/A         G2563T       CAG to CAT       Q57H       13.00       N/A         G25429T       GT A to TTA       V13L       0.10       N/A         G25429T       GT A to TTA       V202L       2.64       N/A         G25906C       GGT to CGT       G172R       2.32						
G28975C       ATG to ATC       M234I       5.58       N/A         C28472T       CCT to TCT       P67S       3.09       N/A         G29399A       GCT to ACT       A376T       5.14       N/A         C29366T       CCA to TCA       P365S       5.64       N/A         G29402T       GAT to TAT       D377Y       1.29       N/A         C28887T       ACT to ATT       T205I       1.47       N/A         C29466T       GCA to GTA       A398V       0.78       N/A         C27046T       ACG to ATG       T175M       0.02       N/A         NS3       G25907T       GGT to GTT       G172V       2.98       N/A         R       G25563T       CAG to CAT       Q57H       13.00       N/A         G25429T       GTA to TTA       T223I       1.87       N/A         G2596T       GTA to TTA       V13L       0.10       N/A         G25996T       GTA to TTA       V202L       2.64       N/A         A25505G       CAA to CGA       Q38R       2.46       N/A         A25505G       CAA to CGA       Q38R       2.46       N/A         A25505G       GAT to CTA       H37L						
C28472T       CCT to TCT       P67S       3.09       N/A         G29399A       GCT to ACT       A376T       5.14       N/A         C29366T       CCA to TCA       P365S       5.64       N/A         G29402T       GAT to TAT       D377Y       1.29       N/A         C28887T       ACT to ATT       T205I       1.47       N/A         C29466T       GCA to GTA       A398V       0.78       N/A         M       A26530G       GAT to GGT       D3G       0.42       N/A         M       A26530G       GAT to GGT       D3G       0.42       N/A         NS3       G25907T       GGT to GTT       G172V       2.98       N/A         NS3       G25617T       AAG to AAT       K75N       0.39       N/A         G25563T       CAG to CAT       Q57H       13.00       N/A         G2560T       ACT to ATT       T223I       1.87       N/A         G25996T       GTA to TTA       V13L       0.10       N/A         G25996T       GTA to TTA       V202L       2.64       N/A         A25505G       CAA to CGA       Q38R       2.46       N/A         A25505G       GAT to CT						
G29399A       GCT to ACT       A376T       5.14       N/A         C29366T       CCA to TCA       P365S       5.64       N/A         G29402T       GAT to TAT       D377Y       1.29       N/A         C28887T       ACT to ATT       T205I       1.47       N/A         C29466T       GCA to GTA       A398V       0.78       N/A         M       A26530G       GAT to GGT       D3G       0.42       N/A         M       A26530G       GAT to GGT       D3G       0.42       N/A         NS3       G25907T       GGT to GTT       G172V       2.98       N/A         NS3       G25617T       AAG to AAT       K75N       0.39       N/A         G25663T       CAG to CAT       Q57H       13.00       N/A         G25600T       ACT to ATT       T223I       1.87       N/A         G25996T       GTA to TTA       V13L       0.10       N/A         G25996T       GTA to TA       V202L       2.64       N/A         A25505G       CAA to CGA       Q38R       2.46       N/A         A25505G       CAA to CGA       Q38R       2.46       N/A         NS7b       AT27866TA <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
C29366T       CCA to TCA       P365S       5.64       N/A         G29402T       GAT to TAT       D377Y       1.29       N/A         C28887T       ACT to ATT       T205I       1.47       N/A         C29466T       GCA to GTA       A398V       0.78       N/A         M       A26530G       GAT to GGT       D3G       0.42       N/A         M       A26530G       GAT to GGT       D3G       0.02       N/A         NS3       G25907T       GGT to GTT       G172V       2.98       N/A         NS3       G25617T       AAG to AAT       K75N       0.39       N/A         G25663T       CAG to CAT       Q57H       13.00       N/A         G25429T       GTA to TTA       V13L       0.10       N/A         G25996T       GTA to TTA       V202L       2.64       N/A         A25505G       CAA to CGA       Q38R       2.46       N/A         A25505G       GAT to CGT       G172R       2.32       N/A         NS7b       AT27866TA       CAT to CTA       H37L       0.058       N/A						
G29402T       GAT to TAT       D377Y       1.29       N/A         C28887T       ACT to ATT       T205I       1.47       N/A         C29466T       GCA to GTA       A398V       0.78       N/A         M       A26530G       GAT to GGT       D3G       0.42       N/A         NS3       G25907T       GGT to GTT       G172V       2.98       N/A         NS3       G25907T       GGT to ATG       T175M       0.02       N/A         Q25617T       AAG to AAT       K75N       0.39       N/A         G2563T       CAG to CAT       Q57H       13.00       N/A         G2560T       ACT to ATT       T223I       1.87       N/A         G25996T       GTA to TTA       V13L       0.10       N/A         G25996T       GTA to TTA       V202L       2.64       N/A         A25505G       CAA to CGA       Q38R       2.46       N/A         M25906C       GGT to CGT       G172R       2.32       N/A         NS7b       AT27866TA       CAT to CTA       H37L       0.058       N/A						
C28887T       ACT to ATT       T205I       1.47       N/A         C29466T       GCA to GTA       A398V       0.78       N/A         M       A26530G       GAT to GGT       D3G       0.42       N/A         C27046T       ACG to ATG       T175M       0.02       N/A         NS3       G25907T       GGT to GTT       G172V       2.98       N/A         G25617T       AAG to AAT       K75N       0.39       N/A         G2563T       CAG to CAT       Q57H       13.00       N/A         G2560T       ACT to ATT       T223I       1.87       N/A         G25996T       GTA to TTA       V13L       0.10       N/A         G25996T       GTA to TTA       V202L       2.64       N/A         A25505G       CAA to CGA       Q38R       2.46       N/A         M25906C       GGT to CGT       G172R       2.32       N/A         NS7b       AT27866TA       CAT to CTA       H37L       0.058       N/A						
C29466T         GCA to GTA         A398V         0.78         N/A           M         A26530G         GAT to GGT         D3G         0.42         N/A           C27046T         ACG to ATG         T175M         0.02         N/A           NS3         G25907T         GGT to GTT         G172V         2.98         N/A           Q25617T         AAG to AAT         K75N         0.39         N/A           G25563T         CAG to CAT         Q57H         13.00         N/A           G2560T         ACT to ATT         T223I         1.87         N/A           G25996T         GTA to TTA         V13L         0.10         N/A           G25996T         GTA to TTA         V202L         2.64         N/A           A25505G         CAA to CGA         Q38R         2.46         N/A           NS7b         AT27866TA         CAT to CTA         H37L         0.058         N/A						
M         A26530G         GAT to GGT         D3G         0.42         N/A           C27046T         ACG to ATG         T175M         0.02         N/A           NS3         G25907T         GGT to GTT         G172V         2.98         N/A           G25617T         AAG to AAT         K75N         0.39         N/A           G25563T         CAG to CAT         Q57H         13.00         N/A           C26060T         ACT to ATT         T223I         1.87         N/A           G25429T         GTA to TTA         V13L         0.10         N/A           G25996T         GTA to TTA         V202L         2.64         N/A           A25505G         CAA to CGA         Q38R         2.46         N/A           M25906C         GGT to CGT         G172R         2.32         N/A           NS7b         AT27866TA         CAT to CTA         H37L         0.058         N/A						
C27046T         ACG to ATG         T175M         0.02         N/A           NS3         G25907T         GGT to GTT         G172V         2.98         N/A           G25617T         AAG to AAT         K75N         0.39         N/A           G25563T         CAG to CAT         Q57H         13.00         N/A           C26060T         ACT to ATT         T223I         1.87         N/A           G25429T         GTA to TTA         V13L         0.10         N/A           G25996T         GTA to TTA         V202L         2.64         N/A           A25505G         CAA to CGA         Q38R         2.46         N/A           MS7b         AT27866TA         CAT to CTA         H37L         0.058         N/A	М					
NS3         G25907T         GGT to GTT         G172V         2.98         N/A           G25617T         AAG to AAT         K75N         0.39         N/A           G25563T         CAG to CAT         Q57H         13.00         N/A           C26060T         ACT to ATT         T223I         1.87         N/A           G25429T         GTA to TTA         V13L         0.10         N/A           G25996T         GTA to TTA         V202L         2.64         N/A           A25505G         CAA to CGA         Q38R         2.46         N/A           G25906C         GGT to CGT         G172R         2.32         N/A           NS7b         AT27866TA         CAT to CTA         H37L         0.058         N/A						
G25617T         AAG to AAT         K75N         0.39         N/A           G25563T         CAG to CAT         Q57H         13.00         N/A           C26060T         ACT to ATT         T223I         1.87         N/A           G25429T         GTA to TTA         V13L         0.10         N/A           G25996T         GTA to TTA         V202L         2.64         N/A           A25505G         CAA to CGA         Q38R         2.46         N/A           G25906C         GGT to CGT         G172R         2.32         N/A           NS7b         AT27866TA         CAT to CTA         H37L         0.058         N/A	NS3					
G25563T         CAG to CAT         Q57H         13.00         N/A           C26060T         ACT to ATT         T223I         1.87         N/A           G25429T         GTA to TTA         V13L         0.10         N/A           G25996T         GTA to TTA         V202L         2.64         N/A           A25505G         CAA to CGA         Q38R         2.46         N/A           G25906C         GGT to CGT         G172R         2.32         N/A           NS7b         AT27866TA         CAT to CTA         H37L         0.058         N/A						
C26060T         ACT to ATT         T223I         1.87         N/A           G25429T         GTA to TTA         V13L         0.10         N/A           G25996T         GTA to TTA         V202L         2.64         N/A           A25505G         CAA to CGA         Q38R         2.46         N/A           G25906C         GGT to CGT         G172R         2.32         N/A           NS7b         AT27866TA         CAT to CTA         H37L         0.058         N/A			CAG to CAT			
G25429T         GTA to TTA         V13L         0.10         N/A           G25996T         GTA to TTA         V202L         2.64         N/A           A25505G         CAA to CGA         Q38R         2.46         N/A           G25906C         GGT to CGT         G172R         2.32         N/A           NS7b         AT27866TA         CAT to CTA         H37L         0.058         N/A						
G25996T         GTA to TTA         V202L         2.64         N/A           A25505G         CAA to CGA         Q38R         2.46         N/A           G25906C         GGT to CGT         G172R         2.32         N/A           NS7b         AT27866TA         CAT to CTA         H37L         0.058         N/A			GTA to TTA	V13L		
A25505G         CAA to CGA         Q38R         2.46         N/A           G25906C         GGT to CGT         G172R         2.32         N/A           NS7b         AT27866TA         CAT to CTA         H37L         0.058         N/A			GTA to TTA		2.64	
G25906C         GGT to CGT         G172R         2.32         N/A           NS7b         AT27866TA         CAT to CTA         H37L         0.058         N/A			CAA to CGA	O38R		N/A
<i>NS7b</i> AT27866TA CAT to CTA H37L 0.058 N/A		G25906C	GGT to CGT			N/A
	NS7b	AT27866TA	CAT to CTA	H37L	0.058	N/A
		C27769T	TCA to TTA	S5L	1.68	N/A
<i>NS8</i> C28087T GCT to GTT A65V 2.68 N/A	NS8		GCT to GTT	A65V	2.68	N/A
T28144C TTA to TCA L84S 0.12 N/A			TTA to TCA	L84S		
C27964T TCA to TTA S24L 3.58 N/A			TCA to TTA	S24L	3.58	N/A
G28077T GTG to TTG V62L 0.27 N/A			GTG to TTG	V62L		N/A
C27972T CAA to TAA Q27stop 21.17 Inactivation of NS8 <sup>20</sup>			CAA to TAA	Q27stop		Inactivation of NS8 <sup>20</sup>
G28048T AGA to ATA R52I 21.14 N/A			AGA to ATA			N/A

493

494 \*Frequency of the mutation as of December 31, 2020.

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

Variant	Gene	Genome Nucleotide Mutation <sup>17</sup>	S or NS	AA mutation <sup>17</sup>	Domain	Frequency* (%)	Effect
B.1.1.7	ORF1ab	C3267T	NS	T1001I		70.7	N/A
		C5388A	NS	A1708D		71.5	N/A
		T6954C	NS	I2230T		70	N/A
		11288-11296 del	NS	ΔS3675/ ΔG3676/ΔF3677		69.2	N/A
		C913T	S			N/A	N/A
		C5986T	S			N/A	N/A
		C14676T	S			N/A	N/A
		C15279T	S			N/A	N/A
		C16176T	S			N/A	N/A
	Spike	21765-21770	NS	$\Delta H69/\Delta V70$	NTD	70.8	Antibody escape43
		21991-21993	NS	ΔΥ144	NTD	0.01	Decrease infectivity Antibody escape <sup>19</sup>
		A23063T	NS	N501Y	RBD	71.9	Increase infectivity virulence and affinite for hACE2 <sup>43</sup>
		C23271A	NS	A570D	SD1	71.6	
		A23403G	NS	D614G	SD2	99.4	Moderate increase transmissibility <sup>43</sup>
		C23709A	NS	P681H	SD2	72.7	N/A
		C23709T	NS	T716I		72.1	N/A
		T24506G	NS	S982A	HR1	71.3	N/A
		G24914C	NS	D1118H		71.2	N/A
	ORF8	C27972T	NS	Q27stop		71.2	Inactivation of NS8 <sup>20</sup>
		G28048T	NS	R52I		71	N/A
		A28111G	NS	Y73C		71.3	N/A
	Μ	T26801C	S			N/A	N/A
	Ν	GAT28280CT A	NS	D3L		70.5	N/A
	Ν	C28977T	NS	S235F		71.4	N/A

## 496 Table 2: Non-synonymous, synonymous and deletion mutations in the B.1.1.7 variant

497

# 498 \*Frequency of the mutation as of February $17^{\text{th}}$ 2021.

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

#### 500 **Table 3:** Non-synonymous mutations and deletions in the B.1.351 variant

Variant	Gene	Genome Nucleotide	A.A mutation <sup>19</sup>	Domain	Frequency *	Effect	<del>501</del>
		Mutation <sup>1</sup>	mutation		(%)		502
B.1.351	ORF1ab	C1059T	T265I		7.3	N/A	503
		G5230T	K1655N		0.57	N/A	505
		A10323G	K3353R		1.7	N/A	
	Spike	C21614T	L18F	NTD	4.5	N/A	504
		A21801C	D80A	NTD	0.47	N/A	
		A22206G	D215G	NTD	0.51	N/A	
		22286-22294	ΔL242/ΔA24 3/ΔL244	NTD	0.311	N/A	505
		G22299T	R246I	NTD	0	N/A	
		G22813T	K417N	RBD	0.50	Antibody escape <sup>24</sup>	506
		G23012A	E484K	RBD	1.74	Antibody escape <sup>43</sup>	
		A23063T	N501Y	RBD	71.9	Increase affinity for hAC	$E2^{43}$
		A23403G	D614G	SD2	99.4	Moderate increase transmissbility <sup>43</sup>	507m
		G23664T	A701V	S1/S2 - S2'	1.40	N/A	
	ORF3a	G25563T	Q57H		10.2	N/A	508
		C25904T	S171L		1.29	N/A	
	Ε	C26456T	P71L		0.55	N/A	
	Ν	C28887T	T205I		2.5	N/A	509

510

511 \*Frequency of the mutation as of February 17<sup>th</sup> 2021.

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

#### **Table 4**: Non-synonymous, synonymous and deletions in the P.1 variant.

Variant	Gene	Genome	S or	A.A	Domain	Frequency*	Effect
		Nucleotide	NS	mutation		(%)	
		Mutation					
P.1	ORF1ab	T733C	S			N/A	N/A
		C2749T	S			N/A	N/A
		C3828T	NS	S1188L		0.22	N/A
		A5648C	NS	K1795Q		0.19	N/A
		11288-11296	NS	ΔS3675/		71.1	N/A
		del		$\Delta G3676/\Delta F3677$			
		C12778T	S			N/A	N/A
		C13860T	S			N/A	N/A
		G17259T	NS	E5665D		0.24	N/A
	Spike	C21614T	NS	L18F	NTD	4.5	N/A
		C21621A	NS	T20N	NTD	0.30	N/A
		C21638T	NS	P26S	NTD	0.44	N/A
		G21974T	NS	D138Y	NTD	0.28	N/A
		G22132T	NS	R190S	NTD	0.73	N/A
		A22812C	NS	K417T	RBD	0.11	N/A
		G23012A	NS	E484K	RBD	1.7	Antibody
							escape <sup>43</sup>
		A23063T	NS	N501Y	RBD	71.9	Increase
							affinity for
							hACE243
		A23403G	NS	D614G	SD2	99.4	Moderate
							increase in
							transmissbility43
		C23525T	NS	H655Y	SD2	0.25	N/A
		C24642T	NS	T1027I	S2	0.20	N/A
	ORF8	G28167A	NS	E92K		0.30	N/A
		Ins28269-28273	S			N/A	N/A
	Ν	C28512G	NS	P80R		0.18	N/A

514

515 \*Frequency of the mutation as of February  $17^{\text{th}} 2021$ .

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

## 517 **Table 5:** Efficacy of vaccines against SARS-CoV-2 variants.

Vaccine	hCoV-	B.1.1.7	B.1.351	P.1	
	19/Wuhan/WIV-				
	4/2019				
Pfizer-BioNTech	95.0% <sup>38</sup>	~ 95.0% <sup>30</sup>	2/3 reduction in	15.1-fold	
			neutralization <sup>36</sup>	decrease <sup>37</sup>	
Moderna	94.1% <sup>39</sup>	~ 94.1% <sup>34</sup>	6.4 reduction $in^{34}$	N/A	
			titers		
Oxford-AstraZeneca	$70.4\%^{40}$	74.6% <sup>33</sup>	21.9% <sup>35</sup>	N/A	

518

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

#### 520 FIGURE LEGENDS

Figure 1: Variation of mutation frequency in SARS-CoV-2 genes. The occurrence and frequency of
mutations in various SARS-CoV-2 genes are presented for the time period between December 2019 to
December 2020. SARS-CoV-2 genes are represented with non-structural proteins (NSPs) and the function
on the genes in parentheses. Graphs were generated using RStudio.

525

Figure 2: Geographic location and timeline of dominant mutations in NSP12, S, and N genes. A)
Frequency of S protein mutations with corresponding geographic maps. B) Frequency of RdRp mutations
with corresponding geographic maps. C) Frequency of Nucleoprotein mutations with corresponding
geographic maps. D) Mutations reaching a frequency higher than 50% between December 2019 and
December 2020. A low frequency of reported cases of the mutations is represented in white, while higher
frequencies are represented in red. All maps were taken from GISAID. Graphs were generated using
RStudio and Biorender.

533

**Figure 3: Structural rendering of most frequent mutation sin the S protein.** A) Surface representation of hACE2 (yellow) in complex with S protein trimers illustrated in grey, blue, and magenta. Recurrent mutations are represented in green. Cartoon representation of B) A222V, C) S477N, D) L18F, E) D614G in open conformation and F) D614G in closed conformation. Reference sequence residues are illustrated in green, and the mutant amino acid is represented in purple. The red circles illustrate the steric clash when the mutations are inserted into the structure. Graphs were generated using PyMOL.

540

Figure 4: Frequency of B.1.1.7, B.1351, P.1, D614G, and reference variants. Database variants
frequency were analyzed from December 2019, to February 17<sup>th</sup>, 2021. The hCoV-19/Wuhan is the
reference strain, and hCoV-19/D614G is representing the D614G mutation in the S protein. B.1.1.7,
B.1.3531, and P.1 represent the UK, South African, and Brazilians variants. \*(overlapping curves).

545

Figure 5: Frequency of B.1.1.7 spike protein mutations with structural confirmation and genome
map. A & B) Colour representation of S protein subdomains with mutations of the B.1.1.7 variant in red.
NTD (green), RBD (blue), SD1 (purple), SD2 (light blue), and S2 (magenta) are illustrated. The other S
protein monomers are displayed in grey and white. C) Frequency of the mutations in the S protein,

Castonguay et al., 2020

Genome Evolution of SARS-CoV-2

B.1.1.7 variant from December 2019 to February 17<sup>th</sup> 2021. D) Interaction of the N501Y (red) mutation in
the RBD (blue) of S protein with hACE2 (yellow). The dash lines indicate interactions with adjacent
residues. E) Genome of the SARS-CoV-2 B.1.1.7 variant with identified nucleotide substitutions and
deletions. Graphs were generated using Biorender, PyMOL, and RStudio. \*(overlapping curves).

554


Figure 6: Frequency of B.1.351 spike protein mutations with structural confirmation and genome 555 556 map. A & B) Colour representation of S protein subdomains with mutations of the B.1.351 variant in 557 orange. NTD (green), RBD (blue), SD1 (purple), SD2 (light blue), and S2 (magenta) are illustrated. The 558 other S protein monomers are illustrated in grey and white. C) Frequency of the mutations in the S protein B.1.351 variant from December 2019 to February 17th 2021. Interaction of D) 417N with C102 Nab 559 (green), E) 484K with C121 Nab (light pink), and F) 501Y with hACE2 (yellow). The mutant residues are 560 561 illustrated in orange, and the dashed lines represent interactions with adjacent residues. G) Genome of the 562 SARS-CoV-2 B.1.351 variant with identified nucleotide substitutions or deletions. Graphs were generated 563 using Biorender, PyMOL, and RStudio. \*(overlapping curves).

564


565 Figure 7: Frequency of P.1 spike protein mutations with structural confirmation and genome map. A& B) Colour representation of S protein subdomains with mutations of the P.1 variant in black. NTD 566 567 (green), RBD (blue), SD1 (purple), SD2 (light blue), and S2 (magenta) are illustrated. The other S protein monomers are illustrated in grey and white. C) Frequency of P.1 variant S protein mutations from 568 December 2019 to February 17th 2021. Interaction of D) 417T with C102 Nab (green), E) 484K with 569 570 C121 Nab (light pink), and F) 501Y with hACE2 (yellow). The mutations are coloured in black and 571 interaction with adjacent residues are demonstrated by dashed lines. G) Genome of the SARS-CoV-2 P.1 variant with identified nucleotides substitution, deletions, and insertions. Figures were generated using 572 573 Biorender, PyMOL and RStudio. \*(overlapping curves).

574


# Figure 8: Interactions of K417, E484, and N501 of the S protein with neutralizing antibodies and hACE2. A) Interaction of K417 (blue) with C102 Nab (green) residues. B) Interaction of E484 (blue) with C121 Nab (light pink). C) Interaction of N501 (blue) with hACE2 (yellow) Dashes lines indicate interactions between residues. The graphs were generated using PyMOL.





# Figure 2




# Figure 3
















# Figure 5







G22813T---G23012A---A23063T---


A23403G

C23664T-

C21614T---A21801C---A22206G---

Δ22286-22294 G22299T








Figure 8

